SKK
RIGL icon

Shepherd Kaplan Krochuk’s Rigel Pharmaceuticals RIGL Stock Holding History

Shepherd Kaplan Krochuk’s Portfolio RIGL Stock Details RIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-4,572
Closed -$139K – 353
2015
Q4 		$139K Sell
4,572
-7,096
-61% -$215K 0.04% 319
2015
Q3 		$288K Buy
11,668
+2,964
+34% +$88.5K 0.08% 188
2015
Q2 		$279K Buy
+8,704
New +$332K 0.05% 244

Other funds holding RIGL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Shepherd Kaplan Krochuk's RIGL Position: Q1 2016 in Review

Shepherd Kaplan Krochuk sold out of Rigel Pharmaceuticals (RIGL) in Q1 2016, closing a stake of 4,572 shares — an estimated $139K sold.

Shepherd Kaplan Krochuk first reported a position in RIGL in Q2 2015 and held it in 3 quarters. The position peaked at $288K in Q3 2015. 120 funds tracked by Wall St. Rank hold RIGL as of Q1 2016.

  • Shepherd Kaplan Krochuk reported no remaining Rigel Pharmaceuticals position as of Q1 2016 after selling out during the quarter.
  • Shepherd Kaplan Krochuk sold 4,572 Rigel Pharmaceuticals shares in Q1 2016, an estimated $139K.
  • Shepherd Kaplan Krochuk first reported a position in Rigel Pharmaceuticals in Q2 2015 and held it in 3 quarters.
  • Shepherd Kaplan Krochuk's Rigel Pharmaceuticals position peaked at $288K in Q3 2015.
  • 120 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q1 2016.

Based on Shepherd Kaplan Krochuk's 13F filing for Q1 2016, filed 16 May 2016.